Advertisement

An Evidence-Based Practice Approach to Evaluating Biotechnologically Derived Medications

  • James P. McCormackEmail author
Chapter

Abstract

Recent advances in pharmaceutical biotechnology have led to the development of many different therapeutic proteins. These technologies have given credence to the legitimate promise that we, at some point, may be able to more closely match some specific patients with the most effective and safe drugs at an individualized dose—personalized/precision medicine. Importantly, these therapeutic proteins should be incorporated into clinical practice just like any other treatment option, which is by using the best available evidence and balancing benefits and harms.

Keywords

Shared-decision making Personalized medicine Precision medicine Evidence-based practice 

References

  1. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B (2013) Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 4:CD006602Google Scholar
  2. Blauvelt A, Papp KA, Griffiths CEM et al (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 76:405–417CrossRefGoogle Scholar
  3. ElDib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC (2016) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 7:CD006663Google Scholar
  4. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med 345:9–16CrossRefGoogle Scholar
  5. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427CrossRefGoogle Scholar
  6. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722CrossRefGoogle Scholar
  7. Sindelar RD (2013) Genomics, other “Omic” technologies, personalized medicine. In: Crommelin DJA, Sindelar RD, Meibohm B (eds) Pharmaceutical biotechnology, 4th edn. Springer, New York, pp 190–221Google Scholar
  8. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A (2016) Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388:31–44CrossRefGoogle Scholar
  9. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP, International Fabry Disease Study Group (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Faculty of Pharmaceutical SciencesUniversity of British ColumbiaVancouverCanada

Personalised recommendations